<DOC>
	<DOCNO>NCT00317876</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , cyclophosphamide , donor bone marrow transplant help stop growth abnormal cell . It also stop patient 's immune system reject donor 's bone marrow . The donated bone marrow stem cell may replace patient 's immune system help destroy remain abnormal cell . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine methotrexate transplant may stop happen . PURPOSE : This phase I trial study side effect best dose cyclophosphamide treat patient undergo donor bone marrow transplant Fanconi 's anemia .</brief_summary>
	<brief_title>Cyclophosphamide Treating Patients Who Are Undergoing Donor Bone Marrow Transplant Fanconi 's Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Decrease conditioning-related toxicity cyclophosphamide without decrease engraftment rate &lt; 90 % patient undergoing allogeneic bone marrow transplantation Fanconi 's anemia . OUTLINE : This multicenter , dose-finding study cyclophosphamide . - Nonmyeloablative conditioning regimen : Patients receive cyclophosphamide IV day -5 -2 . Cohorts 5-10 patient receive decrease dos cyclophosphamide optimal dose ( OD ) determine . The OD define dose ≥ 4 5 patient achieve engraftment &lt; 1 10 patient experience dose-limiting toxicity . - Allogeneic bone marrow transplantation ( BMT ) : Patients undergo allogeneic BMT day 0 . - Graft-vs-host-disease ( GVHD ) prophylaxis : Patients receive cyclosporine orally IV twice daily begin day -1 continue day 49 , follow taper day 50-180 absence GVHD . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Fanconi 's anemia chromosome fragility diepoxybutane ( DEB ) mitomycin C test Hemoglobin ≤ 8.0 g/dL , absolute granulocyte count ≤ 1,000/mm^3 , platelet count ≤ 50,000/mm^3 No refractory anemia excess blast , refractory anemia excess blast transformation , acute leukemia HLAidentical relate donor available PATIENT CHARACTERISTICS : Glomerular filtration rate ≥ 30 % predict age No liver disease ( e.g. , active hepatitis moderate severe portal fibrosis/cirrhosis biopsy ) No symptomatic cardiac insufficiency symptomatic arrhythmia No disease would severely limit probability survival No HIV seropositivity Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Fanconi anemia</keyword>
</DOC>